CSF2 and acute respiratory distress syndrome: In a small clinical study, inhaled sargramostim (yeast-derived rhu GM-CSF) significantly improved oxygenation (p = 0.0035) without side effects in patients with severe ARDS (Herold et al., 2014), demonstrating GM-CSF is well-tolerated in the alveolar space.